Decreased expression of complement regulatory proteins, CD55 and CD59, on peripheral blood leucocytes in patients with type 2 diabetes and macrovascular diseases

Chinese Medical Journal

Volumn 122, Issue 18, 2009, Pages 2123-2128

  Ma, Xi Wen ^a   Chang, Zhi Wen ^a   Qin, Ming Zhao ^a   Sun, Ying ^b   Huang, Hui Lian ^a   He, Yan ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Gansu Provincial Design and Research Institute of Environmental Science   (China)

Author keywords

CD55; CD59; Diabetes mellitus, type 2; Diabetic angiopathies

Indexed keywords

ACUTE PHASE PROTEIN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; REGULATOR PROTEIN;

ACUTE PHASE RESPONSE; ADULT; AGE; AGED; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; B SCAN; BLOOD PRESSURE; CAROTID ARTERY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG USE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; LEUKOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD55; ANTIGENS, CD59; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED;

EID: 70350602353     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.18.009     Document Type: Article

References (28)

1. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996; 61: 201-283.
2. Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N, Hays AP. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol 2000; 99: 55-62. (Pubitemid 30093439)
3. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol- anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002; 51: 3499-3504. (Pubitemid 35403456)
4. Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004; 53: 2653-2661. (Pubitemid 39299275)
5. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 1989; 9: 802-811.
6. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
7. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-467. (Pubitemid 46184197)
8. Wagenknecht LE, D'Agostino R Jr, Savage PJ, O'Leary DH, Saad MF, Haffner SM. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 999-1005.
9. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109 (23 Suppl 1): III39-III43. (Pubitemid 38786442)
11. Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002; 91: 696-703. (Pubitemid 35204952)
12. Liu YM, He JC, Yang JG, Liu YY, Yan X, Zhao L, et al. The effect of atorvastatin on the expression of CD55, CD59 in patients with hyperlipidemia. Chin J Cardiol (Chin) 2005; 33: 1075-1079.
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
14. Hernández-Campo PM, Martín-Ayuso M, Almeida J, López A, Orfao A. Comparative analysis of different flow cytometry-based immunophenotypic methods for the analysis of CD59 and CD55 expression on major peripheral blood cell subsets. Cytometry 2002; 50: 191-201. (Pubitemid 37517318)
15. Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531. (Pubitemid 40696142)
16. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001; 1: 445-459. (Pubitemid 32197543)
17. Accardo-Palumbo A, Triolo G, Colonna-Romano G, Potestio M, Carbone M, Ferrante A, et al. Glucose-induced loss of glycosyl-phosphatidylinositol- anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells. Diabetologia 2000; 43: 1039-1047.
18. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444. (Pubitemid 23046633)
19. Høgåsen AK, Würzner R, Abrahamsen TG, Dierich MP. Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol 1995; 154: 4734-4740.
20. Christmas SE, de la Mata Espinosa CT, Halliday D, Buxton CA, Cummerson JA, Johnson PM. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes. Immunology 2006; 119: 522-528.
21. Ross, R. Atherosclerosis-an inflamematory disease. N Engl J Med 1999; 340: 115-126.
22. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004; 30: 73-80.
23. Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1214-1219. (Pubitemid 34215153)
24. Shang DY, Ma SM, Liu YM, Ma XW, He JC. A study of the relationship between complement C3, C4, properdin, complement regulatory proteins CD55, CD59 and carotid artery intima-media thickness. Chin Circ J (Chin) 2006; 21: 279-281.
25. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
26. Metz CN, Brunner G, Choi-Muira NH, Nguyen H, Gabrilove J, Caras IW, et al. Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J 1994; 13: 1741-1751. (Pubitemid 24114726)
27. Deeg MA, Bowen RF, Williams MD, Olson LK, Kirk EA, LeBoeuf RC. Increased expression of GPI-specific phospholipase D in mouse models of type 1 diabetes. Am J Physiol Endocrinol Metab 2001; 281: E147-E154. (Pubitemid 32911762)
28. Kurtz TA, Fineberg NS, Considine RV, Deeg MA. Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D. Metabolism 2004; 53: 138-139. (Pubitemid 38168881)